Building Quality Indicators to Improve Care for Adults With Congenital Heart Disease  by Gurvitz, Michelle et al.
Journal of the American College of Cardiology Vol. 62, No. 23, 2013
 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.07.099Building Quality Indicators to Improve Care for
Adults With Congenital Heart Disease
Michelle Gurvitz, MD, MS,* Ariane Marelli, MD, MPH,y Rita Mangione-Smith, MD, MPH,z
Kathy Jenkins, MD, MPH*
Boston, Massachusetts; Montreal, Quebec, Canada; and Seattle, Washington
Delphi Expert Panel Co-Chairs and Members: Michelle Gurvitz MD, MS (Panel Co-Chair),
Ariane Marelli MD, MPH (Panel Co-Chair), Curt Daniels MD, William Davidson MD,
Elyse Foster MD, Michael Landzberg MD, Daniel Murphy MD, Erwin Oechslin MD,
Judith Therrien MD, Gary Webb MD, Roberta Williams MD
Working Group Members: Jamil Aboulhosn MD, Craig Broberg MD, Stephen Cook MD,
Michael Earing MD, Joseph Kay MD, Paul Khairy MD, PhD, Karen Kuehl MD, MPH,
Andrew Mackie MD, MS, Alexander Opotowsky MD, MPH, Jo Ann Nieves MSN,
Disty Pearson PA-C, Candice Silversides MD, MS, Anne Marie Valente MDFrom the *D
Pediatrics, H
ology, McG
zDepartmen
School of M
Number 7K
(Dr. GurvitObjectives Tepartment of Cardiology,
arvard Medical School, B
ill University Health C
t of Pediatrics, Seattle C
edicine, Seattle, Washi
23HL095908-02 from t
z). The content is solelyhis study sought to develop quality indicators (QIs) for outpatient management of adult congenital heart disease
(ACHD) patients.Background There are no published QIs to promote quality measurement and improvement for ACHD patients.Methods Working groups of ACHD experts reviewed published data and United States, Canadian, and European guidelines to
identify candidate QIs. For each QI, we speciﬁed a numerator, denominator, period of assessment, and data source.
We submitted the QIs to a 9-member panel of international ACHD experts. The panel rated the QIs for validity and
feasibility in 2 rounds on a scale of 1 to 9 using the RAND/University of California–Los Angeles modiﬁed-Delphi
method, and ﬁnal QI selection was on the basis of median scores.Results A total of 62 QIs were identiﬁed regarding appropriateness and timing of clinical management, testing, and test
interpretation. Each QI was ascertainable from health records. After the ﬁrst round of rating, 29 QIs were accepted,
none were rejected, and 33 were equivocal; on the second round, 55 QIs were accepted. Final QIs included: 8 for
atrial septal defects; 9 for aortic coarctation; 12 for Eisenmenger; 9 for Fontan; 9 for D-transposition of the great
arteries; and 8 for tetralogy of Fallot.Conclusions This project resulted in development of the ﬁrst set of QIs for ACHD care based on published data, guidelines, and
a modiﬁed Delphi process. These QIs provide a quality of care assessment tool for 6 ACHD conditions. This rigorously
designed set of QIs should facilitate measuring and improving the quality of care for this growing group of
patients. (J Am Coll Cardiol 2013;62:2244–53) ª 2013 by the American College of Cardiology FoundationThe purpose of improving quality of care for adult
congenital heart disease (ACHD) patients is to provide
health services that increase the likelihood of desired
health outcomes and are consistent with current profes-
sional knowledge (1). The goal in providing quality careBoston Children’s Hospital and Department of
oston, Massachusetts; yDepartment of Cardi-
enter, Montreal, Quebec, Canada; and the
hildren’s Hospital, University of Washington
ngton. This project was supported by Award
he National Heart, Lung and Blood Institute
the responsibility of the authors and does notis to decrease variation in practice patterns, improve
health outcomes for patients with these life-long condi-
tions, and provide a common language for dialogue
among patients, healthcare providers, administrators, and
policy makers.necessarily represent the ofﬁcial views of the National Heart, Lung and Blood Institute
or the National Institutes of Health. Dr. Marelli is funded by the Heart and Stroke
Foundation of Canada and the Canadian Institute for Health Research. All other
authors have reported that they have no relationships relevant to the contents of this
paper to disclose. Drs. Gurvitz and Marelli contributed equally to this work.
Manuscript received March 4, 2013; revised manuscript received June 28, 2013,
accepted July 1, 2013.
Abbreviations
and Acronyms
ACHD = adult congenital
heart disease
ASD = atrial septal defect
CHD = congenital heart
disease
COA = coarctation of the
aorta
QI = quality indicator
RCT = randomized clinical
trials
TGA = d-transposition of the
great arteries
TOF = tetralogy of Fallot
JACC Vol. 62, No. 23, 2013 Gurvitz et al.
December 10, 2013:2244–53 Quality Measurement in Adult Congenital Heart Disease
2245Measurement is the ﬁrst step to quality improvement. In
the 1960s, Avedis Donabedian described a framework
for quality assessment that formed the foundation of most
quality of care research methods used today (2). This
Donabedian model divides aspects of healthcare quality into
structure, process, and outcome to describe the effects of health
care on outcomes. We constructed a conceptual framework on
the basis of the Donabedian structure-process-outcome model
to illustrate this for ACHD patients (2). This model, shown
in Figure 1, illustrates the integrated effects of structural,
process, and outcome aspects of health care for ACHD
patients and includes moderating patient factors.
Developing and implementing clinical care guidelines
and assessing adherence to them using structure and process
quality indicators (QIs) can provide a baseline for quality
improvement. However, guidelines differ from QIs in im-
portant ways. Guidelines are recommendations for care
meant to be applied prospectively to individual patients,
whereas QIs are measures applied retrospectively to a group
of patients to assess if a care process was delivered or not. (3)
For adults with congenital heart disease (CHD), com-
prehensive guidelines for care have been available since 1998,
when Canada published the ﬁrst set (4). Subsequently,
Europe and the United States also published their own sets of
guidelines, andCanada andEurope reported theirmost recent
revisions in 2010 (5–10). All sets of guidelines were developed
in similar manners using the opinions of national and inter-
national experts in ACHD and related specialties, as well as
available published data and evidence. The recommendations
are meant to be comprehensive for caring for ACHD patients
with any lesion. Much of the evidence is Level 1C (expert
consensus opinion) (11), because that was the best available
when the guidelines were written.Figure 1 ACHD Quality of Care Conceptual Model
Conceptual framework on the basis of the Donabedian model of quality of care illustratin
including moderating patient factors (2).The purpose of this project
was to develop quality-of-care
assessment tools for ACHD
patients on the basis of published
guidelines to determine the
extent to which the guidelines
are being applied and to arrive at
a set of measures that can be
evaluated, revised, and updated
as new data become available.
Given the breadth of congenital
heart defects and the wide scope
of inpatient, outpatient, and pro-
cedural care, we chose to focus
our attention on outpatient care
of common adult congenital
heart lesions for this ﬁrst set of QIs. Our objectives were to
develop valid and feasible QIs for outpatient management of
6 ACHD conditions: tetralogy of Fallot (TOF), secundum
atrial septal defect (ASD), coarctation of the aorta (COA),
dextro (D)-transposition of the great arteries (TGA) with
atrial switch operation, single ventricle with Fontan opera-
tion, and Eisenmenger syndrome. Patients with ASD
commonly survive into adulthood, and another 3 lesions
(TOF, COA, and TGA) are highly represented in ACHD
clinics. This is not surprising, as palliative and reparative
surgeries for TOF, COA, and TGA were among the earliest
CHD surgeries performed in the 1940s to 1960s. We
included the remaining 2 conditions, Eisenmenger
syndrome and single-ventricle physiology with Fontan
surgery, due to the complexity of underlying disease and
cardiovascular physiology, requiring highly specialized
medical management.g the integrated effects of structural, process, and outcome aspects of health care,
Table 1
Metric Elaboration for TOF Illustrating the Steps in
Achieving Operationalization on the Basis of Review of
Published Data
CHD Condition
TOF
Your Name:
Metric 1 Minimum of yearly scheduled return visit with
cardiologist who has ACHD expertise for
patients with TOF repair and followed by an
ACHD specialist.
Question we are asking: are ACHD
cardiologists scheduling patients with
TOF repair for yearly visits?
Metric operationalized Scheduled return visit with a cardiologist with
ACHD expertise at least yearly.
Numerator Patients who had or were recommended to
have visit with a cardiologist with ACHD
expertise at least every 12 months.*
Denominator Patients with TOF repair followed by a
cardiologist with ACHD expertise
Source of Data Medical record
Rationale
Evidence Level IC
Structure
Process O
Outcome
Guideline support Yes
Period of Assessment 12 months
References (12)y
*“Had” or were “recommended to have” accounts for patient noncompliance. yIn terms of visit, U.S.
guidelines do not specify the components of the visit, but they indicate in the text features of the
physical examination to be sought. In terms of surveillance, the Canadian guidelines say “regularly”
but do not specify “yearly,” and the ESC guidelines say “periodic which in most patients is annually.”
A visit here is deﬁned as a check-up independent of acute care issues.
ACHD ¼ adult congenital heart disease; CHD ¼ congenital heart disease; TOF ¼ tetralogy of
Fallot.
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Deﬁnitions of anatomic subgroups. Our goal in choosing
the lesions and the anatomic subgroups was to attempt to
capture a large but consistent proportion of patients
currently followed in ACHD clinics. Patients with ASD
are those with an isolated secundum ASD either repaired
with or without a residual shunt or unrepaired. Patients
with COA are all those with repaired or unrepaired COA
distal to the left subclavian artery with or without bicuspid
aortic valve. Patients with ES are all those with cyanosis
and pulmonary vascular disease in association with a prior
right-to-left shunt. The Fontan subgroup includes all
forms of single-ventricle physiology with any type of
Fontan repair. Patients with TGA are only those with
D-TGA who have undergone an atrial bafﬂe repair of the
Mustard or Senning type. The TOF subgroup includes
patients with uncomplicated TOF and complete intracar-
diac repair; the subgroup is not intended to include
complex TOF with pulmonary atresia and major aorto-
pulmonary collaterals or combination lesions, such as TOF
and atrioventricular canal.
Working groups. Published guidelines from the United
States, Canada, and Europe and relevant medical published
data were reviewed by working groups of ACHD experts to
obtain candidate QIs (5–10). To develop the preliminary
QIs, working groups composed of 3 to 5 ACHD clinicians
were organized for each condition. The working groups
developed up to 10 QIs per condition. The QIs were
designed to be applied to patients being followed in any
outpatient cardiology practice, not speciﬁcally ACHD
practices. After the working groups completed their litera-
ture reviews and developed draft QIs for their assigned
conditions, all guidelines and QIs for the different condi-
tions were systematically reviewed and revised for consis-
tency by the primary investigators (M.G. and A.M.). This
led to further deﬁnition and reﬁnement of the QIs before
presentation to the panel of experts. These revisions ensured
that each QI included the speciﬁcation of a numerator,
a denominator, a data source, a period of assessment (when
applicable), an evidence grade, and supporting published
data (Table 1) (12). All QIs were classiﬁed as structure or
process indicators. There were no outcome indicators
proposed. Levels of Evidence were deﬁned in the typical
number and letter system as follows: I) intervention is useful
and effective; IIa) weight of evidence/opinion is in favor
of usefulness/efﬁcacy; IIb) usefulness/efﬁcacy is less well
established by evidence/opinion; III) intervention is not
useful/effective and may be harmful; A) data from many
large randomized clinical trials (RCTs); B) data from fewer
smaller RCTs, careful analysis of nonrandomized studies,
and observational registries; and C) expert consensus (11).
RAND/UCLA Delphi panel methodology. We used the
RAND/University of California–Los Angeles (UCLA)
appropriateness method and modiﬁed Delphi process to
arrive at the ﬁnal set of QIs (13,14). This methodologyincludes the extensive review of published data, as
described previously. The candidate QIs (Table 2) (7,10)
were submitted to a 9-member panel of international
ACHD experts for 2 rounds of rating for validity and
feasibility on a scale of 1 to 9. Experts for the panel were
chosen on the basis of nominations from the following
organizations: the American College of Cardiology (ACC),
American Heart Association, Canadian Adult Congenital
Heart Network, International Society for Adult Congenital
Heart Disease, and the medical advisory board of the Adult
Congenital Heart Association. Only 2 initial panel invitees
declined: 1 due to prior commitments and 1 due to travel
distance from Europe. The ﬁnal panel was composed of
ACHD physicians from the United States and Canada
with backgrounds in adult cardiology, pediatric cardiology,
or both. The experts were highly-experienced congenital
cardiologists and had spent from 12 to 40 years in cardi-
ology practice. Experts in catheterization and imaging were
included, but no electrophysiology or transplant specialists
were on the panel due to the lack of these subspecialties
among the nominees.
The expert panel rated the QIs in 2 rounds. All indicators
were individually graded by each panelist for validity and
feasibility on an ordinal scale of 1 to 9. A high validity score
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2247meant that the indicator was clinically relevant, it was
supported by available scientiﬁc evidence or expert con-
sensus, and adherence to it would be considered delivery of
high quality care. A high validity score also indicated that
a large proportion of the determinants of adherence to the
QI were under the provider’s or clinic’s control, and
compliance with the indicator would confer health beneﬁts.
A high feasibility score meant that the data needed to
determine eligibility and adherence to the indicator would
be readily available in the average medical record (or should
be available), the data would likely be unbiased, and esti-
mates of performance on the basis of medical records data
are likely to be reliable (14).
The ﬁrst set of ratings were performed and returned to the
primary investigators (A.M. and M.G.) by e-mail. Median
feasibility and validity scores and mean absolute deviations
from the median were calculated for each indicator. The
median was used to measure the central tendency of the
panelists’ ratings, and the mean absolute deviation from the
median was used to measure the dispersion of ratings (15).
Indicators with high median ratings (7 to 9 for validity and 4
to 9 for feasibility) and rated with agreement (or minimal
dispersion of scores) according to the mean absolute devia-
tion from the median score were considered “accepted,”
whereas those with low ratings (1 to 3 for validity and/or
feasibility) were rejected. Indicators with median ratings
between these 2 ranges (validity median 4 to 6) and/or
scored by panelists with disagreement or an indeterminate
level of agreement on the basis of the mean absolute devi-
ation from the median (wide spread of scores) were listed for
further discussion in the next rating round. We contacted
each panelist after the ﬁrst round to discuss his or her
individual results to better understand outlier scores and to
address any speciﬁc questions or concerns of the panelists.
The second round of ratings by the experts occurred at the
in-person Delphi panel meeting in May 2011 in Boston,
Massachusetts. The participants discussed the QIs that had
been identiﬁed for further consideration after the ﬁrst round
of scoring. The panelists proposed minor additions, dele-
tions, or modiﬁcations to the set of indicators, particularly
those indicators with low-moderate scores or those with
signiﬁcant disagreement among the panelists as assessed by
the mean absolute deviation from the median score.
Following the discussions, each panelist individually re-
scored the QIs for validity and feasibility on the 9-point
Delphi scale. These results were scored and analyzed in
the same way as the ﬁrst round of scoring. Those indicators
that had a median score of 7 to 9 on validity and 4 to 9 on
feasibility and that were scored without signiﬁcant
disagreement were included in the ﬁnal set of QIs; the
others were discarded.
Expert deﬁnitions. Reﬁning the QIs required the devel-
opment of deﬁnitions for the term “expert” in relation to
multiple aspects of CHD. In the ACHD guidelines,
many of the recommendations for care include the need
for an ACHD expert or for an expert in clinical care,catheterization, or imaging. The guidelines, however, do not
deﬁne the cited expertise. We, therefore, developed perti-
nent deﬁnitions for the purposes of this project. The ACHD
expert deﬁnition was developed with the knowledge that
a board certiﬁcation for ACHD was being considered, so
this deﬁnition would need to be able to be revised in the
future. The American Board of Medical Specialties
announced the creation of a subspecialty certiﬁcation in
ACHD in December 2012, and the examination is expected
to be available by 2015.
We based the expert deﬁnitions on 2 sources. First, we
considered published guidelines, including those for adult
and pediatric cardiovascular training (16–18), and the
Bethesda conference recommendations on what constitutes
an ACHD regional center (19). Second, we consulted the
Adult Congenital Heart Association clinic directory, which
includes self-reported data from self-identiﬁed ACHD
centers. To determine which elements most commonly
comprise the proﬁle of self-reported ACHD experts, we
looked at the distribution of 3 variables extracted from
the Adult Congenital Heart Association web site: 1) the
number of years in ACHD practice; 2) the percent
time spent in ACHD practice; and 3) the total number of
patient visits per center per year. For each of these variables,
we obtained a histogram of distribution on the basis of
available data as well as, median, and interquartile range
data. These data and suggestions for expert deﬁnitions
were presented to the expert panel for input, revision, and
adjustment. The ﬁnal deﬁnitions were divided into clinical
and technical expertise domains and are presented in
Table 3.Results
QIs and results of panel ratings. The working groups
and primary investigators proposed a total of 62 QIs for
consideration. After the ﬁrst round of scoring, none were
rejected, 29 scored high enough on validity and feasibility to
be accepted, and 33 warranted further discussions or
modiﬁcation. After all controversial indicators were dis-
cussed for a given condition, panelists rescored the indicators
for that condition. This second round of scoring resulted in
55 (89%) indicators being retained, including 8 for ASDs, 9
for aortic coarctation, 12 for Eisenmenger, 9 for Fontan, 9
for D-TGA, and 8 for TOF. All of the 55 retained QIs are
recommended to assess quality of care. Six QIs were
removed for low validity and 1 QI was removed due to
substantial dispersion of ratings and, thus, disagreement
among the panelists (Table 2).
One example of a recommended QI would be an annu-
al visit with an ACHD cardiologist for patients with Fontan
procedure. For patients in specialty ACHD clinics, this
would include an annual visit. However, for patients fol-
lowed in non-ACHD cardiology clinics, this would include
the need for an annual referral to an ACHD expert. This QI
passed, but other QIs were rejected. Rejection of a QI does
Table 2
All Candidate Quality Indicators and Rating Scores for Round 1 and Round 2 Ratings by the Expert Panel Separated by Lesion,
Including Categorization of Indicators by Process and Structure Within Each Lesion and the Level of Evidence of Each Indicator
Score Round 1 Score Round 2
Recommended/
Rejected
General Description (Level of Evidence) Validity Feasibility Validity Feasibility
Secundum ASD
Process indicators
Demonstration of shunting across ASD by echocardiogram (IC) 7.0, 2.0
(2–9)
9.0, 1.1
(4–9)
7.0, 1.8
(2–9)
8.0, 1.7
(2–9)
Recommended
Report of presence of absence of right ventricular enlargement in
unrepaired ASD by echocardiogram (IC)
7.0, 1.0
(4–9)
9.0, 0.7
(7–9)
8.0, 0.7
(6–9)
9.0, 0.7
(7–9)
Recommended
Echocardiogram report of pulmonary artery pressure by tricuspid
regurgitation velocity (IC)
8.0, 0.6
(6–9)
8.0, 1.3
(3–9)
8.0, 0.3
(7–9)
9.0, 0.7
(6–9)
Recommended
Pulmonary vein anatomy determined prior to intervention (IC) 9.0, 0.4
(7–9)
8.0, 1.2
(4–9)
9.0, 0.4
(7–9)
8.0, 0.8
(5–9)
Recommended
Patient had appropriate indication for cardiac catheterization (IC) 5.0, 1.9
(2–9)
8.0, 1.4
(4–9)
8.5, 1.1
(4–9)
8.5, 1.0
(6–9)
Recommended
Patient did not have appropriate indication for ASD closure (IIIB) 7.0, 1.0
(6–9)
8.0, 0.9
(6–9)
8.0, 0.8
(6–9)
8.0, 1.0
(6–9)
Recommended
Annual clinic surveillance with cardiologist with ACHD expertise
for patients with ASD closure and pulmonary hypertension,
arrhythmia, ventricular, or valve dysfunction (IC)
7.0, 1.1
(5–9)
7.0, 2.1
(3–9)
8.0, 0.7
(6–9)
9.0, 0.2
(8–9)
Recommended
Appropriate counseling of SBE prophylaxis (IIaC) 8.0, 1.1
(5–9)
7.0, 1.0
(6–9)
9.0, 1.3
(5–9)
7.0, 1.0
(6–9)
Recommended
Cardioversion to attempt restoration of sinus rhythm if
atrial ﬁbrillation (IA)
6.0, 1.4
(4–9)
7.0, 1.2
(4–9)
3.0, 1.0
(1–6)
5.0, 2.3
(1–9)
Rejected
Anticoagulation if atrial ﬁbrillation in patient with or without ASD
closure (IA)
8.0, 1.7
(3–9)
9.0, 0.2
(8–9)
7.0, 2.1
(1–8)
8.0, 1.9
(1–9)
Rejected
Coarctation of Aorta (COA)
Process indicators
Minimum of annual return visit with cardiologist with
ACHD expertise for patients with COA repair followed by
ACHD expert (IC)
5.0, 1.6
(3–9)
9.0, 0.8
(7–9)
9.0, 0.4
(7–9)
9.0, 0.2
(8–9)
Recommended
Annual check of bilateral upper extremity blood pressures
(BP) and either lower extremity BP (IC)
8.0, 0.8
(5–9)
8.0, 0.9
(5–9)
8.0, 0.6
(7–9)
8.0, 0.7
(6–9)
Recommended
Right upper extremity BP measured at each visit
(IB [10], IC [7])
8.0, 0.6
(7–9)
9.0, 0.1
(8–9)
9.0, 0.6
(7–9)
9.0, 0.0
(9–9)
Recommended
Any transthoracic echocardiogram includes proximal
descending aortic Doppler gradient (IB [10], IC [7])
7.0, 1.3
(2–9)
8.0, 1.3
(5–9)
7.0, 0.9
(5–9)
9.0, 0.6
(6–9)
Recommended
MRI or CT evaluation of complete thoracic aorta at least
every 5 years for patients with repaired COA (IC)
8.0, 1.1
(5–9)
9.0, 0.3
(8–9)
9.0, 0.7
(7–9)
9.0, 0.2
(8–9)
Recommended
Documentation of aortic valve morphology (IC) 9.0, 0.4
(7–9)
9.0, 1.2
(4–9)
9.0, 0.6
(7–9)
9.0, 0.2
(7–9)
Recommended
Measurement of the ascending aorta by
echocardiogram, CT, or MRI at least every 2 years
for those with bicuspid aortic valve or enlarged
ascending aorta (IB [10], IC [7])
7.0, 1.2
(3–9)
8.0, 0.9
(6–9)
8.0, 0.6
(7–9)
9.0, 0.6
(7–9)
Recommended
Minimum of annual visit with cardiologist and at least
every 3 year referral to a cardiologist with
ACHD expertise for patients with repaired COA not
followed by ACHD expert (IC)
6.0, 1.7
(3–7)
7.0, 1.1
(5–8)
9.0, 0.4
(7–9)
9.0, 0.4
(7–9)
Recommended
Structure indicator
Catheter-based intervention on the COA site should
be performed by a CHD specialist with cardiac
catheterization expertise (IC)
9.0, 1.4
(3–9)
9.0, 1.3
(3–9)
9.0, 0.4
(7–9)
9.0, 0.6
(6–9)
Recommended
Continued on the next page
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2248not mean it is not considered to be important; it may mean
that the evidence base was not as strong or that the data was
not feasible to collect in a reasonable and accurate manner.
For example, for patients with ASD, “cardioversion to
attempt restoration of sinus rhythm if atrial ﬁbrillation” was
rejected after the second round of voting. As can be seen inTable 2, panel 1, in Round 2 the median validity score
decreased from 6.0 to 3.0 and the median feasibility score
decreased from 7.0 to 5.0 with an increase in deviation to
2.3. This should not be taken to mean that the panel did not
perceive the restoration of sinus rhythm to be important in
the management of atrial ﬁbrillation in patients with ASD.
Eisenmenger Syndrome
Process indicators
Minimum of annual return visit with cardiologist with
ACHD expertise for patients with ES followed by
ACHD expert (IC)
8.0, 0.9
(6–9)
8.0, 0.7
(7–9)
8.0, 0.7
(7–9)
9.0, 0.2
(8–9)
Recommended
Annual measurement of pulse oximetry (IC) 8.0, 0.7
(7–9)
9.0, 0.0
(9–9)
9.0, 0.4
(7–9)
9.0, 0.0
(9–9)
Recommended
Annual hemoglobin or hematocrit (IC) 9.0, 1.1
(4–9)
9.0, 0.0
(9–9)
9.0, 0.6
(6–9)
9.0, 0.0
(9–9)
Recommended
Annual iron panel (iron, transferring saturation, total binding
capacity, ferritin) (IC)
7.0, 1.7
(3–9)
9.0, 0.3
(7–9)
7.0, 1.2
(5–9)
9.0, 0.2
(7–9)
Recommended
Discussion about use of pulmonary vasodilators in ES patients
WHO functional class III or worse at least every
24 months (IIaC)
8.0, 0.9
(5–9)
9.0, 0.8
(6–9)
8.0, 0.9
(6–9)
8.0, 1.2
(4–9)
Recommended
Annual creatinine as measure of renal function (IC) 8.0, 1.1
(3–9)
9.0, 0.1
(8–9)
9.0, 0.6
(7–9)
9.0, 0.2
(8–9)
Recommended
Annual assessment of functional capacity by either
cardiopulmonary exercise test or 6-min walk test (IC)
6.0, 1.2
(3–9)
9.0, 0.6
(6–9)
8.0, 0.9
(6–9)
9.0, 0.2
(8–9)
Recommended
Recommendation to avoid pregnancy addressed annually (IB) 8.0, 1.1
(5–9)
8.0, 1.1
(6–9)
8.0, 0.8
(7–9)
8.0, 0.7
(7–9)
Recommended
Annual recommendation for use of SBE prophylaxis (IB) 9.0, 0.7
(6–9)
9.0, 0.4
(6–9)
9.0, 0.6
(6–9)
9.0, 0.7
(6–9)
Recommended
Annual recommendation for inﬂuenza vaccine (IC) 9.0, 0.7
(5–9)
9.0, 0.7
(5–9)
9.0, 0.5
(7–9)
9.0, 0.3
(7–9)
Recommended
No phlebotomy in ES patients unless symptoms of hyperviscosity
and erythrocytosis without anemia or iron deﬁciency (IC)
8.0, 0.7
(5–9)
7.0, 1.4
(4–9)
8.0, 0.8
(6–9)
7.0, 1.0
(6–9)
Recommended
Minimum of yearly scheduled visit or referral to cardiologist with
ACHD expertise for patients with ES not followed by
ACHD expert (IC)
7.0, 1.1
(3–9)
7.0, 1.1
(5–9)
8.0, 0.8
(6–9)
8.0, 0.7
(7–9)
Recommended
Annual measurement of uric acid (IC) 6.0, 1.6
(3–9)
9.0, 0.2
(8–9)
5.0, 2.1
(1–9)
9.0, 1.2
(2–9)
Rejected
Fontan
Process indicators
Minimum of yearly scheduled return visit with a cardiologist with
ACHD expertise for patients with Fontan surgery followed by
ACHD expert (IC)
9.0, 0.7
(7–9)
9.0, 0.3
(7–9)
9.0, 0.7
(7–9)
9.0, 0.1
(8–9)
Recommended
Oxygen saturation at rest at least annually (IIaC) 8.0, 1.1
(6–9)
9.0, 0.1
(8–9)
9.0, 0.4
(7–9)
9.0, 0.2
(7–9)
Recommended
Anticoagulation if atrial shunt, atrial thrombus, or atrial
arrhythmia (IC)
8.0, 1.4
(3–9)
9.0, 0.8
(4–9)
9.0, 0.3
(8–9)
9.0, 0.5
(8–9)
Recommended
Pregnancy or contraception counseling by cardiologist with
ACHD expertise annually (IC)
7.0, 1.4
(3–9)
7.0, 1.4
(5–9)
9.0, 0.7
(7–9)
9.0, 0.8
(7–9)
Recommended
Annual measurement of liver function (IIaC) 7.0, 0.9
(5–9)
9.0, 0.2
(7–9)
8.0, 0.7
(7–9)
9.0, 0.0
(9–9)
Recommended
Documentation of hepatitis C status (not graded)* 9.0, 1.8
(2–9)
8.0, 1.1
(4–9)
9.0, 0.9
(3–9)
9.0, 0.1
(8–9)
Recommended
Yearly visit with or referral to a cardiologist with ACHD expertise
for patients with Fontan surgery not followed by
ACHD expert (IC)
8.0, 0.9
(5–9)
7.0, 1.2
(4–9)
9.0, 0.3
(7–9)
9.0, 0.9
(6–9)
Recommended
Fontan patients with onset of atrial arrhythmia should have
TEE or MRI to evaluate for thrombus (IC)
5.0, 1.9
(2–9)
8.0, 0.7
(7–9)
3.0, 2.0
(1–8)
8.0, 1.0
(3–9)
Rejected
Structure indicators
Annual and comprehensive echocardiogram (MRI or CT may
substitute) read by cardiologist with CHD imaging expertise (IC)
7.0, 1.2
(5–9)
9.0, 0.6
(6–9)
8.0, 0.8
(6–9)
9.0, 0.2
(8–9)
Recommended
Diagnostic or interventional cardiac catheterization performed by
CHD specialist with cardiac catheterization expertise (IC)
9.0, 0.4
(7–9)
8.0, 1.1
(6–9)
9.0, 0.2
(8–9)
9.0, 0.6
(7–9)
Recommended
Table 2 Continued
Continued on the next page
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2249It means that a signiﬁcant number of panelists did not feel
the evidence strongly supported which groups would beneﬁt
most and how this data would be reliably collected or
speciﬁcally measured.Type of indicators and supportive evidence. The pro-
posed indicators were either related to the healthcare process
(85%) or structure (15%). No pure outcome indicators were
proposed or included. In total, the QIs addressed the broad
TGA
Process indicators
Minimum of yearly scheduled return visit with cardiologist who
has ACHD expertise for patients with TGA and atrial bafﬂe
repair followed by ACHD expert (IC)
7.0, 0.6
(7–9)
9.0, 0.3
(7–9)
8.0, 0.7
(7–9)
9.0, 0.0
(9–9)
Recommended
At least annual electrocardiogram (IB) 9.0, 1.1
(5–9)
9.0, 0.0
(9–9)
9.0, 0.8
(7–9)
9.0, 0.0
(9–9)
Recommended
Pacemaker for symptomatic bradyarrhythmia or sick sinus
syndrome (IB)
9.0, 1.3
(5–9)
8.0, 1.0
(5–9)
9.0, 1.0
(5–9)
9.0, 1.1
(5–9)
Recommended
Pregnancy or contraception counseling by cardiologist with ACHD
expertise annually (IC)
7.0, 1.2
(3–9)
8.0, 1.3
(5–9)
9.0, 0.9
(7–9)
8.0, 0.8
(6–9)
Recommended
Appropriate counseling regarding SBE prophylaxis (IIaB) 9.0, 1.3
(4–9)
9.0, 1.0
(5–9)
9.0, 1.4
(4–9)
9.0, 0.8
(7–9)
Recommended
Minimum of yearly scheduled visit with or referral to cardiologist
with ACHD expertise for patients with TGA and atrial bafﬂe
repair not followed by ACHD expert (IC)
7.0, 1.3
(5–9)
7.0, 1.0
(5–9)
9.0, 0.6
(7–9)
7.0, 0.7
(6–9)
Recommended
Valve repair or replacement for moderate to severe systemic
atrioventricular valve regurgitation with normal ejection fraction
(IC)
6.0, 0.6
(4–7)
6.0, 1.2
(3–8)
3.0, 1.2
(1–6)
6.0, 1.4
(3–8)
Rejected
Structure indicators
Echocardiographic imaging in TGA with atrial bafﬂe repair should
be performed by CHD specialist with imaging expertise (IB)
9.0, 0.9
(6–9)
9.0, 1.2
(5–9)
9.0, 0.6
(7–9)
9.0, 0.7
(7–9)
Recommended
Diagnostic cardiac catheterization should be performed by CHD
specialist with cardiac catheterization expertise (IC)
9.0, 0.9
(6–9)
8.0, 1.1
(5–9)
9.0, 0.4
(7–9)
9.0, 0.4
(7–9)
Recommended
Interventional cardiac catheterization in TGA with atrial bafﬂe
repair should be performed by CHD specialist with cardiac
catheterization expertise (IC)
8.0, 1.1
(5–9)
8.0, 1.2
(5–9)
9.0, 0.4
(7–9)
9.0, 0.4
(7–9)
Recommended
Tetralogy of Fallot
Process indicators
Annual return visit with cardiologist with ACHD expertise for
patients with TOF repair followed by ACHD expert (IC)
7.0, 1.2
(3–9)
9.0, 0.3
(8–9)
8.0, 0.3
(7–9)
9.0, 0.1
(8–9)
Recommended
At least annual surveillance electrocardiogram (ECG) in patients
with TOF repair (IC)
8.0, 1.1
(5–9)
9.0, 0.2
(8–9)
9.0, 0.6
(7–9)
9.0, 0.0
(9–9)
Recommended
Surveillance of width of QRS complex on 12-lead ECG in patients
with TOF repair (IB)
8.0, 1.0
(6–9)
9.0, 1.1
(6–9)
8.0, 0.7
(7–9)
8.0, 0.9
(6–9)
Recommended
Appropriate endocarditis prophylaxis counseling in patients with
repaired TOF (IIaB)
7.0, 1.1
(5–9)
9.0, 0.9
(6–9)
9.0, 0.3
(7–9)
9.0, 0.6
(7–9)
Recommended
Minimum of yearly scheduled visit with or referral to cardiologist
with ACHD expertise for patients with repaired TOF and not
followed by ACHD expert (IC)
7.0, 0.9
(5–9)
7.0, 0.8
(5–9)
8.0, 0.6
(7–9)
9.0, 0.7
(7–9)
Recommended
Internal cardiac deﬁbrillator implanted in patients with
documented sustained and/or resuscitated ventricular
arrhythmia (IC)
9.0, 0.6
(5–9)
9.0, 1.3
(5–9)
5.0, 2.3
(1–9)
5.0, 2.3
(1–9)
Rejected
Transthoracic echocardiography at least every 12 months in
patients with TOF repair (IB [10], IC [7])
7.0, 1.0
(3–9)
9.0, 0.2
(8–9)
5.0, 4.0
(1–9)
5.0, 4.0
(1–9)
Rejected
Structure indicators
MRI assessment of right ventricular ejection fraction in adults with
TOF repair at least every 5 years and interpreted by
CHD specialist with imaging expertise (IC)
7.0, 1.1
(3–8)
7.0, 1.0
(6–9)
8.0, 0.7
(7–9)
9.0, 0.3
(7–9)
Recommended
Echocardiographic assessment of adults with TOF repair
interpreted by CHD specialist with imaging expertise (IB [10],
IC [7])
8.0, 1.1
(6–9)
8.0, 1.0
(6–9)
9.0, 0.4
(7–9)
9.0, 0.4
(7–9)
Recommended
Diagnostic or interventional cardiac catheterization in
TOF patients performed by CHD specialist with cardiac
catheterization expertise (IC)
7.0, 1.4
(3–9)
9.0, 1.1
(6–9)
9.0, 0.6
(7–9)
9.0, 0.6
(7–9)
Recommended
Values are median, mean absolute deviation (range). *This indicator was recommended by the working group but is not covered in any of the sets of available guidelines.
ACHD ¼ adult congenital heart disease; ASD ¼ atrial septal defect; BP ¼ blood pressure; CHD ¼ congenital heart disease; COA ¼ coarctation of the aorta; CT ¼ computed tomography; ES ¼ Eisenmenger
syndrome; MRI ¼ magnetic resonance imaging; TGA ¼ d-loop transposition of the great arteries; TEE ¼ transesophageal echocardiography; TOF ¼ tetralogy of Fallot; WHO ¼ World Health Organization.
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2250categories of clinical testing (45%), appointments (20%),
procedures (15%), and counseling (18%). The evidence level
supporting each indicator was either determined by the
published guidelines or assigned by 2 of the authors (A.M.and M.G.) based on available literature and evidence
criteria (11). The evidence supporting the measures was
predominantly level IC (41 of 62), with 2 measures graded
IA, 12 measures rating IB, 3 rating IIaB, 4 rating IIaC,
Table 3 Deﬁnitions Used to Qualify ACHD and CHD Expertise
A cardiologist with ACHD expertise A cardiologist who has received level 2 or level 3 ACHD training as per published deﬁnitions
OR for those who have not received formal training
A cardiologist who spends at least 20% over 9 years or 50% over 5 years of his/her time in ACHD practice.
This deﬁnition uses the lowest interquartile range of the practice patterns extracted from the Adult Congenital
Heart Association.
CHD specialist with imaging or
cardiac catheterization expertise
1. An adult cardiologist with ACHD expertise who has level 3 training in echocardiography, MRI, or
cardiac catheterization as deﬁned by the adult training guidelines.
OR
2. A pediatric cardiologist with ACHD expertise and with advanced echocardiography, MRI, or
cardiac catheterization expertise as deﬁned in the pediatric training guidelines. OR
3. A pediatric cardiologist with advanced technical training or adult cardiologist with level 3 technical training,
both as deﬁned by training guidelines, who work in a team with at least 1 ACHD specialist immediately
available, on site, for face to face consultation.
Abbreviations as in Table 2.
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2251and 1 rating IIIB. The total is greater than 62, as the
evidence supporting some of the indicators was graded
differently in different guideline documents or literature.
Table 2 shows corresponding levels of evidence and metric
type for QIs that were retained or rejected. Indicators
common to multiple lesions are shown in Table 4.
Discussion
To our knowledge, this is the ﬁrst effort to develop a valid
and feasible set of QIs to assess the quality of outpatient
ACHD care. Although the ACHD population is growing
and guidelines for care exist, prior to this effort, there were
no established measures to assess quality of care using these
guideline standards (20). We demonstrated that published
literature and guideline documents can be utilized to inform
the development of candidate QIs for ACHD care. We
engaged international experts applying the RAND/UCLA
modiﬁed-Delphi method to select a ﬁnal set of QIs. This
quality measure development effort constitutes an important
step in facilitating the assessment and improvement of
quality care for ACHD patients.
The National Quality Forum has recognized the need to
improve health care in America, leveraging input fromTable 4
Quality Indicators Common to Several of the
CHD Lesions
Quality Indicators CHD Lesions
Annual visit with ACHD specialist ASD closure (if pulmonary hypertension,
arrhythmia, valve disease), COA
(repaired), ES, Fontan, TGA, TOF
Oxygen saturation annually ES, Fontan
Catheterization performed by CHD
catheterization specialist
COA (interventional only), Fontan,
TGA, TOF
Appropriate SBE prophylaxis
counseling
ASD, ES, TGA, TOF
Pregnancy/contraception
discussion annually
ES, Fontan, TGA
Annual 12-lead electrocardiogram TGA, TOF
TTE interpreted by cardiologist
with CHD
imaging expertise
Fontan, TGA, TOF
Abbreviations as in Table 2.multiple stakeholders (21). Quality measurement provides
the basis for understanding where improvements are most
needed and for testing the effectiveness of quality im-
provement interventions. They further provide the basis for
quality reporting (22). Adults with CHD are one of the
fastest growing groups in cardiology (20). They are also one
of a growing number of adult patient groups with chronic
life-long diseases of childhood (23). Despite this, efforts
aimed at quality measurement are scant.
Expert consensus guidelines are written to standardize
care on the basis of the best available evidence. However,
guidelines are applied prospectively and are intended to be
broad in scope and allow margins in applicability on the
basis of the supporting grade of evidence and the subgroups
of patients to which they are applied. Guidelines are ﬂexible
in order to accommodate clinical judgment, and the decision
to follow a guideline remains with the individual physician
in conjunction with his or her patient.
In this effort, we took the next essential step to decreasing
practice variation by developing valid and feasible QIs for the
6 stated conditions informed by clinical guidelines. In
contrast to guidelines, QIs provide speciﬁc measures that are
applied retrospectively to a group of patients to assess the
processes of care received or not received by those patients (3).
QIs should be sufﬁciently supported by scientiﬁc evidence
and/or expert consensus such that failure to implement them
would be considered incongruous with the standards of care
for a particular condition. Thus, QIs provide metrics to
evaluate and measure the quality of care provided and are
often used as a basis for quality improvement initiatives. In
interpreting the ﬁndings of this project, it is recognized that
different QIs might have been recommended or rejected for
particular conditions. The fact that 1 QI is retained or
considered for some lesions but not others does not indicate
that the retained QI may not be generalizable. For example,
an annual 12-lead electrocardiogram is recommended for
TOF and TGA, but not for other conditions. In the other
lesions, although an electrocardiogram may be important,
other QIs were chosen by the working groups or were more
highly rated. QI consideration and recommendation is,
therefore, a composite expression of what experts perceived to
be most feasible and valid for speciﬁc lesion categories.
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conditions such as coronary artery disease, the QIs centering
on the structural and process dimensions of quality were
favored over those representing the outcome dimension.
It is not known if structure and process measures selected
will correlate with outcome, but we anticipate that outcome
measures will be developed in the future as more consistent
clinical data becomes available. At the current time, struc-
ture and process measures of quality would constitute
important steps in shaping quality of care for ACHD
patients (24).
Quality improvement initiatives are increasingly recog-
nized in cardiology as well as in other chronic disease
models. QIs have been developed for the management of
acute myocardial infarction and percutaneous coronary
interventions using national expert panels and a 2-step
modiﬁed-Delphi process similar to the one used in this
project (25,26). In both of these efforts, the majority of
measures selected were related to structure and process
rather than outcome. This is in spite of the fact that there are
signiﬁcantly more studies evaluating medical and interven-
tional outcomes for coronary disease than for CHD.
In pediatric cardiology, there are limited large randomized
trials or long-term outcome studies on which to base quality
improvement initiatives. However, moving forward, efforts
are centering on outcomes evaluation, particularly for
surgical and interventional procedures. There has been pilot
work measuring surgical technical performance in pediatric
congenital heart surgery (27). The components of the
technical performance scores were developed for surgeries on
4 congenital conditions and were agreed upon by expert
consensus opinion. For interventional cardiac catheteriza-
tion, methods have been developed to risk-adjust for case
mix complexity, thus allowing outcome comparisons between
institutions and procedures (28). A recent national effort by
the ACC to develop a catheterization registry and evaluate
procedural outcomes has successfully recruited over 50
centers to participate (29). Outside of procedural outcomes,
there have also been efforts aimed at other areas within
pediatric cardiology that focus more on processes of care. One
such effort is the quality measures working group of the
ACC. One goal of the group is to develop quality metrics
across 8 clinical areas and then to potentially combine the
metrics into an online “scorecard” for the interested CHD
community for internal quality improvement (30).
Other chronic diseases have made signiﬁcant progress in
improving quality of care. The cystic ﬁbrosis model, as
determined by the Cystic Fibrosis Foundation, incorporates
serial establishment of a patient registry, establishment of
a research development program, and a quality improvement
initiative that have been used for program accreditation.
This has led to the development of a culture of group data
collection and transparency when it comes to performance
benchmarking (31). Several efforts are underway in ACHD
care that may enable electronic deployment of the ACHD
metrics developed in this effort to improve knowledgetranslation, decision support, and tracking for reporting
purposes. We expect that consistently and comprehensively
collected data can be organized between providers and
practices, facilitating local and national quality improvement
efforts.
Study limitations. The quality measure development
process used here has inherent limitations. First, we relied
on published data and practice guidelines that are mostly
Level of Evidence: C in the QI development. We also relied
on expert panel opinions. A different panel of experts might
have selected a different set of QIs. Although this is a know-
n and reasonable part of the RAND/UCLA method, it does
impose some uncertainty in the QIs. The ACHD experts
serving on the panel were nominated from multiple national
and international congenital cardiology organizations. We
sought to obtain a wide representation of expert practicing
cardiologists caring for ACHD patients. The fact that no
ACHD electrophysiologist or transplant specialist was in-
cluded in our panel does not indicate that the importance of
those subspecialties was not recognized or that QIs regarding
those topics are not important or valid. It only indicates that, at
the time of this panel, experts representing those specialized
subgroups were not included among the nominees. Future
panels may have different compositions of experts.
Some of the QIs will also be limited by the deﬁnition of
ACHD experts. As board certiﬁcation for ACHD was
only recently approved by the American Board of Medical
Specialties, there were no established references or “gold
standard” criteria to deﬁne the relevant expertise. The pro-
posed “expert” working deﬁnitions are designed to change
as certiﬁcation testing becomes available and policies
change in the future. In this ﬁrst iteration of ACHDQIs, we
sought to cover processes of care where the greatest amount
of agreement exists at the current time on the basis of the
existing published data. CHD is rapidly evolving and our
populations are changing not only in demographics but also
in terms of anatomical and surgical substrates. Like guideline
documents, it is planned that these QIs will be updated on
a regular basis, not only as more data becomes available
but also for speciﬁc types and subgroups of patients. Finally,
development of detailed measure speciﬁcations and ﬁeld
testing are needed to fully operationalize and further validate
these QI metrics.
Conclusions
The elaboration of care guidelines for ACHD patients has
constituted an important initiative in attempting to create
standards of care for this group of patients. They underscore
the need to achieve the highest possible quality of care.
Recognizing the difference between guidelines and QIs, we
leveraged published data and guidelines to develop the ﬁrst
set of QIs for ACHD care. We learned that in our ﬁeld at
this point in time, both the published reports and our expert
panel gravitated towards indicators related to process and
structure of care rather than outcomes. This will allow
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2253reﬁnement of quality of care moving forward. The devel-
opment of these QIs constitutes a pivotal point that will
allow us to begin to measure quality of care being delivered.
In future studies, this ﬁrst iteration of a quality assessment
tool will be tested, updated, reﬁned, and expanded as more
data become available. With this project we have advanced
the process of improving the quality of care for the growing
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